| Autor: |
Weder, C., Baltariu, G. M., Wyler, K. A., Gober, H.-J., Lienert, C., Schluep, M., Radü, E. W., de Libero, G., Kappos, L., Duda, P. W. |
| Předmět: |
|
| Zdroj: |
European Journal of Neurology; Nov2005, Vol. 12 Issue 11, p869-878, 10p, 3 Diagrams, 3 Charts |
| Abstrakt: |
Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text